Sexually Transmitted Diseases and Pre-exposure Prophylaxis (PrEP) to HIV Systematic Review
DOI:
https://doi.org/10.56294/piii2023135Keywords:
PrEP, Sexually Transmission Diseases, HIV, Gonorrhea, Chlamydia, MonkeypoxAbstract
Introduction: Sexually transmitted infections (STDs) constitute a group of very frequent diseases worldwide and an important public health problem. Currently, the positivity of new cases is alarming, which is why it is necessary to renew the preventive strategies and awareness of STDs together with pre-exposure prophylaxis (PrEP) that has proven to be not only effective but also profitable and safe. Objectives: The objective of this Systematic Review of the literature is to evaluate, through the study of scientific publications, the impact, safety, efficacy and controversies that arise from patients with sexually transmitted diseases who are under PrEP therapy for HIV and identify the barriers that exist in the adequate information on the part of the population. Materials and methods: In this systematic review of the literature, research articles published to date on various platforms available on the Internet such as PubMed, Google Schoolar, MedLine, ResearchGate are analyzed in order to obtain reliable data that relationships of sexually transmitted diseases in people on PrEP therapy
References
Moreno-Ribera N, Fuertes-de Vega I, Blanco-Arévalo JL, Bosch-Mestres J, GonzálezCordón A, Estrach-Panella T, et al. Infecciones de transmisión sexual: experiencia de una consulta multidisciplinar en un hospital terciario (2010-2013). Actas Dermo-Sifiliográficas. abril de 2016;107(3):235-41.
InformeVIH_SIDA_2016.pdf [Internet]. [citado 26 de diciembre de 2022]. Disponible en: https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/vigilancia/InformeV IH_SIDA_2016.pdf
rd592_1993.pdf [Internet]. [citado 26 de diciembre de 2022]. Disponible en: http://www.mscbs.es/va/ciudadanos/enfLesiones/enfTransmisibles/sida/docs/rd592_1993.pdf
McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Preexposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic openlabel randomised trial. The Lancet. enero de 2016;387(10013):53-60.
Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. OnDemand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 3 de diciembre de 2015;373(23):2237-46.
Cambiano V, Miners A, Dunn D, McCormack S, Ong KJ, Gill ON, et al. Costeffectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation. The Lancet Infectious Diseases. enero de 2018;18(1):85-94.
Lizardo J. Ministerial Meeting on HIV and Development in Latin America and the Caribbean.
De Melo LD, Sodré CP, Spindola T, Martins ERC, De Oliveira André NLN, da Motta CVV. A prevenção das infecções sexualmente transmissíveis entre jovens e a importância da educação em saúde. Enf Global. 1 de enero de 2022;21(1):74-115.
Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, et al. Postexposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. The Lancet Infectious Diseases. marzo de 2018;18(3):308-17.
Grant RM, Glidden DV. HIV moments and pre-exposure prophylaxis. The Lancet. abril de 2016;387(10027):1507-8.
Cambiano V, Miners A, Dunn D, McCormack S, Ong KJ, Gill ON, et al. Is PreExposure Prophylaxis for HIV prevention costeffective in men who have sex with men in the UK? A modelling and health economic evaluation. Lancet Infect Dis. enero de 2018;18(1):85-94.
Corneli AL, McKenna K, Perry B, Ahmed K, Agot K, Malamatsho F, et al. The Science of Being a Study Participant: FEM-PrEP Participants’ Explanations for Overreporting Adherence to the Study Pills and for the Whereabouts of Unused Pills. JAIDS Journal of Acquired Immune Deficiency Syndromes. 15 de abril de 2015;68(5):578-84.
Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. N Engl J Med. 5 de febrero de 2015;372(6):509-18.
Haberer JE, Bangsberg DR, Baeten JM, Curran K, Koechlin F, Amico KR, et al. Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS. 17 de julio de ;29(11):1277-85.
Beesham I, Dovel K, Mashele N, Bekker LG, Gorbach P, Coates TJ, et al. Barriers to Oral HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Pregnant and Postpartum Women from Cape Town, South Africa. AIDS Behav. septiembre de 2022;26(9):3079-
Ogunbajo A, Storholm ED, Ober AJ, Bogart LM, Reback CJ, Flynn R, et al. Multilevel Barriers to HIV PrEP Uptake and Adherence Among Black and Hispanic/Latinx Transgender Women in Southern California. AIDS Behav. julio de 2021;25(7):2301-15.
Profilaxis previa a la exposición para la infección por VIH entre mujeres africanas - PubMed [Internet]. [citado 28 de diciembre de. Disponible en: https://pubmed.ncbi.nlm.nih.gov/22784040/
Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 12 de agosto de 2021;385(7):595-608.
Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 7 de mayo de 2022;399(10337):1779-89.
Tsui AO, Brown W, Li Q. Contraceptive Practice in Sub-Saharan Africa. Popul Dev Rev. mayo de 2017;43(Suppl Suppl 1):166-91.
ROLLE CP, ONWUBIKO U, JO J, SHETH AN, KELLEY CF, HOLLAND DP. PrEP Implementation and Persistence in a County Health Department Setting in Atlanta, GA. AIDS Behav. octubre de 2019;23(Suppl 3):296-303.
Rao A, Mhlophe H, Comins C, Young K, Mcingana M, Lesko C, et al. Persistence on oral pre-exposure prophylaxis (PrEP) among female sex workers in eThekwini, South Africa, 2016–2020. PLOS ONE. 15 de marzo de;17(3):e0265434.
Coy KC, Hazen RJ, Kirkham HS, Delpino A, Siegler AJ. Persistence on HIV preexposure prophylaxis medication over a 2‐year period among a national sample of 7148 PrEP users, United States, 2015 to 2017. J Int
AIDS Soc. 18 de febrero de 2019;22(2):e25252. 24. Véliz-Burgos A, Dörner-Paris A. Lo individual versus lo comunitario en tiempos de crisis sanitaria. PyR [Internet]. 2020 [citado 26 de diciembre de 2022];8(SPE1). Disponible en: http://revistas.usil.edu.pe/index.php/pyr/article/v iew/502
Recent HIV Testing Among Young Men Who Have Sex with Men in Bangkok and Chiang Mai: HIV Testing and Prevention Strategies Must Be Enhanced in Thailand-PubMed [Internet]. [citado 28 de diciembre de. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26884309/
Evaluación del Programa de Prevención y Atención a las Personas Afectadas por el VIH-SIDA en Asturias 2003-2008.
Kingsberg SA, Schaffir J, Faught BM, Pinkerton JV, Parish SJ, Iglesia CB, et al. Female Sexual Health: Barriers to Optimal Outcomes and a Roadmap for Improved Patient–Clinician Communications. J Womens Health (Larchmt). 1 de abril de 2019;28(4):43243.
Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, et al. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and CommunityBased Sexual Health Services. JAMA Intern Med. 1 de enero de 2016;176(1):75.
Sued O. Innovar para eliminar el VIH/sida en 2030. Actualizaciones en Sida e Infectología [Internet]. 6 de diciembre de 2022 [citado 26 de diciembre de 2022];30. Disponible en: https://revista.infectologia.info/index.php/revist a/article/view/149
Infecciones de transmisión sexual en el contexto de una agresión sexual [Internet]. [citado 26 de diciembre de 2022]. Disponible en: https://www.elsevier.es/es-revistaenfermedades-infecciosas-microbiologiaclinica-28-pdf-S0213005X18303756 31. OPSCDEVT200005_spa.pdf [Internet]. [citado 26 de diciembre de 2022]. Disponible en: https://iris.paho.org/bitstream/handle/10665.2/51951/OPSCDEVT200005_spa.pdf?sequence=6&isAllowed=y
Traeger MW, Cornelisse VJ, Asselin J, Price B, Roth NJ, Willcox J, et al. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection. JAMA. 9 de abril de 2019;321(14):1380.
Werner RN, Gaskins M, Nast A, Dressler C. Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection – A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis. Mugo PM, editor. PLoS ONE. 3 de diciembre de 2018;13(12):e0208107.
Thornhill JP, Palich R, Ghosn J, Walmsley S, Moschese D, Cortes CP, et al. Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series. Lancet. ;400(10367):1953-65.
Tarín-Vicente EJ, Alemany A, AgudDios M, Ubals M, Suñer C, Antón A, et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. Lancet. 2022;400(10353):661-9.
OPSCDEHT220007_spa.pdf [Internet]. [citado 26 de diciembre de 2022]. Disponible en: https://iris.paho.org/bitstream/handle/10665.2/55919/OPSCDEHT220007_spa.pdf?sequence=1&isAllowed=
Cambiano V, Miners A, Dunn D, McCormack S, Gill N, Nardone A, et al. O1 Is pre-exposure prophylaxis for hiv prevention cost-effective in men who have sex with men who engage in condomless sex in the uk? Sex Transm Infect. junio de 2015;91(Suppl 1):A1.1A1.
Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on-demand preexposure prophylaxis for HIV in men who have sex with men: an observational cohort study. The Lancet HIV. septiembre de 2017;4(9):e40210.
Sanchez Conde M. Profilaxis preexposición (PrEP) frente al VIH: eficacia, seguridad e incertidumbres. FARMACIA HOSPITALARIA. 1 de septiembre de;(5):630-7.
Ayerdi-Aguirrebengoa O, Vera-García M, Puerta-López T, Raposo-Utrilla M, Rodríguez-Martín C, Del Romero-Guerrero J. ¿A quién proponer la profilaxis preexposición al virus de la inmunodeficiencia humana? Enfermedades Infecciosas y Microbiología Clínica. mayo de 2017;35(5):299-302.
Mir JF, Mazarío MF, Coll P. Modelos de implementación y acceso a la profilaxis preexposición para el VIH en España. Enfermedades Infecciosas y Microbiología Clínica. mayo de 2020;38(5):234-7.
Kojima N, Davey DJ, Klausner JD. Pre-exposure prophylaxis for HIV infection and new sexually transmitted infections among men who have sex with men. AIDS. 10 de septiembre de 2016;30(14):2251-2.
Jansen K, Steffen G, Potthoff A, Schuppe AK, Beer D, Jessen H, et al. STI in times of PrEP: high prevalence of chlamydia, gonorrhea, and mycoplasma at different anatomic sites in men who have sex with men in Germany. BMC Infect Dis. 7 de febrero de 2020;20:110.
(1) (PDF) Corrección: Incidencia de infecciones de transmisión sexual en hombres que tienen sexo con hombres y que tienen un riesgo sustancial de infección por VIH: un metanálisis de datos de ensayos y estudios observacionales de profilaxis previa a la exposición al VIH [Internet]. [citado 26 de diciembre de 2022]. Disponible en: https://www.researchgate.net/publication/337722416_Correction_Incidence_of_sexually_transmitted_infections_in_men_who_have_sex_with_men_and_who_are_at_substantial_risk_of_HI V_infection_-_A_metaanalysis_of_data_from_trials_and_observationa l_studies.
Díaz YMS, Orlando-Narváez SA, Ballester-Arnal R. Conductas de riesgo hacia la infección por VIH. Una revisión de tendencias emergentes. Ciênc saúde coletiva. abril de 2019;24(4):1417-26.
Cohen MS, Baden LR. Preexposure Prophylaxis for HIV — Where Do We Go from Here? N Engl J Med. 2 de agosto de;367(5):459-61.
Myers GM, Mayer KH. Oral Preexposure Anti-HIV Prophylaxis for HighRisk U.S. Populations: Current Considerations in Light of New Findings. AIDS Patient Care and STDs. febrero de 2011;25(2):63-71. 48. Baeten JM, Strick LB, Lucchetti A, Whittington WLH, Sanchez J, Coombs RW, et al. Herpes Simplex Virus Suppressive Therapy Decreases Plasma and Genital HIV-1 Levels in HSV-2/HIV-1 Co-infected Women: A Randomized, Placebo-Controlled, Cross-Over Trial. J Infect Dis. 15 de diciembre de 2008;198(12):1804-8.
Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir exposure and preexposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 12 de septiembre de 2012;4(151):151ra125.
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral Prophylaxis for HIV-1 Prevention among Heterosexual Men and Women. N Engl J Med. 2 de agosto de 2012;367(5):399-410.
Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. N Engl J Med. 2 de agosto de 2012;367(5):423-34.
Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. junio de 2013;381(9883):2083-90.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Sofía Lorena Contreras Vera, Dr. Gerardo Laube (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
